Navigation Links
Usage of coil better in brain haemorrhage

According to researchers in UK inserting a coil into a weakened blood vessel offers a survival benefit over surgery in brain haemorrhage. The death rate from subarachnoid haemorrhage// - caused by a bursting of a weakened blood vessel in the brain - is up to 40 per cent in the first 24 hours after the event. The standard treatment is an operation to insert a clip to prevent further rupture of the blood vessel.

In recent years, an alternative has been developed, which involves threading a platinum coil through the artery to the weakened area to prevent further bleeding. This is a less invasive option and, to compare the two, researchers at the Radcliffe Infirmary, Oxford, UK have analysed results from 2143 patients from centres in Europe, Australia and North America.

The patients received either the platinum coil or conventional surgery. With the coil, the death or disability rate at one year was 25 per cent, compared to 35 per cent in the surgery group. Clearly, the coil offers some survival benefit. What is now needed is longer-term trials to assess the benefit to the patient and the durability of the coil itself.


'"/>




Page: 1

Related medicine news :

1. Oxygen Usage During Exercise Could Indicate Heart Problems
2. The Usage Of Anti-Inflammatory Drugs Questioned
3. Drug Pramipexole Usage Linked To Gambling Addiction In Parkinsons Patients
4. Generic Drugs Usage In US Can Save $20 Billion – Express Script Surve
5. Safety Of Indian Sex Workers At Risk Due To Poor Condom Usage
6. Dummy Usage Raises Doubts.
7. Usage Of Oral Contraceptives Need Not Be Feared By SLE Patients
8. More The Usage More The Growth In The Adult Brain.
9. Ignorance in the Usage of Pill Persists Among Many Women
10. Vaticans Council Reviews Condom Usage
11. Large Scale Free Access On Usage Of HIV Drugs Could Help In Fighting Its Spread
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Usage coil better brain haemorrhage

(Date:12/6/2009)... -- The University HealthSystem Consortium (UHC) recognized 10 ... in UHC,s Supply Chain Optimization Program. The leaders ... best practices in supply chain program participation. ... winners were determined using 2008 data and based ... and use of UHC resources. ,, Characteristics of ...
(Date:12/6/2009)... in Cambridge have discovered that the loss of a key ... is the first study to show that this kind of ... in Nature . , The study, led by Dr ... Hurles from the Wellcome Trust Sanger Institute, looked at 300 ... entire genome looking for types of mutation known as copy ...
(Date:12/6/2009)... ORLEANS, Dec. 6 Onyx Pharmaceuticals, Inc. ... data from the pivotal Phase 2b 003-A1 study, ... is well-tolerated in heavily pre-treated relapsed and refractory ... at the ASH/ASCO Joint Symposium at the 51st ... (ASH) in New Orleans. Enrollment in this trial ...
(Date:12/6/2009)... Sleep Disorders information and Treatment site www.sleeping-with-a-sleeping-disorder.com ... problems with herbal or natural sleep aids from ... remedies for a good cause. The submissions will ... Sleep Aids ,Encyclopedia, by YOU, to be sold ... site will donate 100% of the proceeds ,from ...
(Date:12/5/2009)... been significant scientific advances in the field of blood ... understanding of how certain diseases progress in order to ... best care. Research presented today at the 51st Annual ... induction therapies for managing multiple myeloma, the importance of ...
Breaking Medicine News(10 mins):Health News:Recognized Top Performers in UHC Supply Chain 2Health News:Genetic studies reveal new causes of severe obesity in childhood 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8
... N.J., Feb. 19 Wyeth (NYSE: WYE ),announced ... Circuit Court,for Baltimore City in Baltimore, Maryland, has granted ... et al. v. Sigma Aldrich, Inc.,et al -- an ... thimerosal-containing vaccines caused him to become autistic., Previously, ...
... schizophrenia also tend to occur in their healthy siblings, ... the Neuroscience of Mental Disorders at Washington University School ... in the brain,s thalamus. , The researchers performed brain ... non-affected siblings and compared the scans with those of ...
... obese have lower concentrations of prostate-specific antigen (PSA) in ... new study led by Duke University Medical Center researchers. ... found in obese and overweight men with prostate cancer ... for heavier patients, and to encourage those patients to ...
... Chicago, CHICAGO, Feb. 19 The following release ... The Chicago Dental Society (CDS) recently polled more than ... adults seeking,braces, and how the current presidential candidates, smiles ... Meeting, one of the largest,displays of dental products in ...
... as a Snack or Condiment is a Healthy Choice ... ... February marks a food,quandary with observances of both Heart-Healthy Month and National ... outside traditional meal times; unfortunately, their snack,choices are not always healthy ones. ...
... -- Researchers and clinicians from the Indiana University School ... distinction between lab and clinic as they debut the ... care model they developed and extensively tested over the ... care is on two groups -- patients with cognitive ...
Other Medicine News:Health News:Wyeth Wins Thimerosal-Autism Case in Maryland Court 2Health News:Wyeth Wins Thimerosal-Autism Case in Maryland Court 3Health News:Siblings of schizophrenia patients display subtle shape abnormalities in brain 2Health News:Overweight and obese men have lower PSA values, even before they get prostate cancer 2Health News:New Guacamole 100-Calorie Packs - The Solution for Clashing February Holidays 2Health News:Merging discovery with therapy: Second generation memory care debuts 2Health News:Merging discovery with therapy: Second generation memory care debuts 3
(Date:12/4/2009)... AstraZeneca (NYSE: AZN ) today announced ... approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets ... Major Depressive Disorder (MDD). SEROQUEL XR is the only ... treat both major depressive disorder as adjunctive therapy and ...
(Date:12/3/2009)... YORK, Dec. 3 Guidepoint Global, LLC , a ... Sleep Apnea Tracker, a monthly longitudinal data release that monitors ... Apnea market. ,, The Sleep Apnea Tracker captures actual ... in the United States from 15 different equipment providers going ...
(Date:12/3/2009)... ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec. ... the signing of an agreement to provide extended ... next-generation sequencing projects performed at Ambry. ... Kammesheidt PhD, Ambry,s CSO said, "Our team at ...
Breaking Medicine Technology:US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 1Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 2Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 3Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 4Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 5Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 6Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 7Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 8Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 9Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 10Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 11Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 12Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 13Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 14Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 15Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 16Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 17Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 18Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 19Sanofi aventis Announces Second Quarter 2009 Results 13244 1Sanofi aventis Announces Second Quarter 2009 Results 13244 2Sanofi aventis Announces Second Quarter 2009 Results 13244 3Sanofi aventis Announces Second Quarter 2009 Results 13244 4Sanofi aventis Announces Second Quarter 2009 Results 13244 5Sanofi aventis Announces Second Quarter 2009 Results 13244 6Sanofi aventis Announces Second Quarter 2009 Results 13244 7Sanofi aventis Announces Second Quarter 2009 Results 13244 8Sanofi aventis Announces Second Quarter 2009 Results 13244 9Sanofi aventis Announces Second Quarter 2009 Results 13244 10Sanofi aventis Announces Second Quarter 2009 Results 13244 11Sanofi aventis Announces Second Quarter 2009 Results 13244 12Sanofi aventis Announces Second Quarter 2009 Results 13244 13Sanofi aventis Announces Second Quarter 2009 Results 13244 14Sanofi aventis Announces Second Quarter 2009 Results 13244 15Sanofi aventis Announces Second Quarter 2009 Results 13244 16Sanofi aventis Announces Second Quarter 2009 Results 13244 17Sanofi aventis Announces Second Quarter 2009 Results 13244 18Sanofi aventis Announces Second Quarter 2009 Results 13244 19Sanofi aventis Announces Second Quarter 2009 Results 13244 20Sanofi aventis Announces Second Quarter 2009 Results 13244 21Sanofi aventis Announces Second Quarter 2009 Results 13244 22Sanofi aventis Announces Second Quarter 2009 Results 13244 23Sanofi aventis Announces Second Quarter 2009 Results 13244 24Sanofi aventis Announces Second Quarter 2009 Results 13244 25Sanofi aventis Announces Second Quarter 2009 Results 13244 26Sanofi aventis Announces Second Quarter 2009 Results 13244 27Narconon Graduate Delivers Drug Education in Florida 53033 1Narconon Graduate Delivers Drug Education in Florida 53033 2
... Pa. and LYON, France, Aug. 1 Sanofi,Pasteur, ... vaccine (Fluzone(R), Influenza Virus Vaccine) in the United,States ... doses of influenza,vaccine began shipping this week following ... Food and Drug Administration (FDA) on,July 14, 2008., ...
... CLL Meets ... Primary Endpoint, COPENHAGEN, ... GSK) announced today positive top-line,results from an interim analysis of the ... chronic lymphocytic,leukemia (CLL) patients with high unmet medical need. At the ...
Other Medicine Technology:Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US 2Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US 3Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US 4Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US 5Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study 2Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study 3Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study 4Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study 5Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study 6
... The RapidPCP test is an ... test. It is,designed for qualitative determination ... above,a cut-off level of 25 ng/mL. ... in the point of care location,and ...
The RapidMTD test is an immunochromatography based one step in vitro test. It is,designed for qualitative determination of methadone in human urine specimens above a,cut-off level of 300 ng/mL. The a...
The RapidBARBITURATE test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of barbiturates and in human urine specimens above a cut-off level of 3...
... With membrane parasite ... and cytoplasm as antigen. ... different antigens than the ... possible to use two ...
Medicine Products: